| scholarly article | Q13442814 |
| P2093 | author name string | Dennis H Oh | |
| Christopher Lau | |||
| Daniel D Bikle | |||
| Jean Y Tang | |||
| Maryam M Asgari | |||
| Teresa Fu | |||
| P2860 | cites work | Randomized, double-blind clinical trial to evaluate the efficacy of topical tacalcitol and sunlight exposure in the treatment of adult nonsegmental vitiligo | Q82643024 |
| Preventing vitamin D toxicity in patients with sarcoidosis | Q83636900 | ||
| Repression of smoothened by patched-dependent (pro-)vitamin D3 secretion | Q21146049 | ||
| Evaluation, Treatment, and Prevention of Vitamin D Deficiency: an Endocrine Society Clinical Practice Guideline | Q22306207 | ||
| The 2011 report on dietary reference intakes for calcium and vitamin D from the Institute of Medicine: what clinicians need to know | Q22306208 | ||
| Regulation of human epidermal keratinocyte differentiation by the vitamin D receptor and its coactivators DRIP205, SRC2, and SRC3 | Q24311835 | ||
| A cohort study of vitamin D intake and melanoma risk | Q24646333 | ||
| Diet and melanoma in a case-control study | Q28265654 | ||
| Vitamin D toxicity, policy, and science | Q28269556 | ||
| Identification of mutations in the human PATCHED gene in sporadic basal cell carcinomas and in patients with the basal cell nevus syndrome | Q28273158 | ||
| Risk assessment for vitamin D | Q28282327 | ||
| Pharmacokinetics of vitamin D toxicity | Q28290163 | ||
| Calcium plus vitamin D supplementation and the risk of colorectal cancer | Q28297713 | ||
| Vitamin D receptor gene polymorphisms, serum 25-hydroxyvitamin D levels, and melanoma: UK case-control comparisons and a meta-analysis of published VDR data | Q33483893 | ||
| Inverse association between serum 25(OH) vitamin D levels and non-melanoma skin cancer in elderly men | Q33716053 | ||
| Impaired repair of cyclobutane pyrimidine dimers in human keratinocytes deficient in p53 and p63 | Q33772427 | ||
| Association of prediagnostic serum vitamin D levels with the development of basal cell carcinoma | Q33792610 | ||
| Overview of the Cohort Consortium Vitamin D Pooling Project of Rarer Cancers | Q33942605 | ||
| Inactivation of the vitamin D receptor enhances susceptibility of murine skin to UV-induced tumorigenesis | Q34021575 | ||
| Vitamin D and systemic cancer: is this relevant to malignant melanoma? | Q34144103 | ||
| Human serum 25-hydroxycholecalciferol response to extended oral dosing with cholecalciferol | Q34166759 | ||
| Vitamin D3 inhibits hedgehog signaling and proliferation in murine Basal cell carcinomas | Q34939822 | ||
| Inverse association between dietary vitamin D and risk of cutaneous melanoma in a northern Italy population | Q34995493 | ||
| Vitamin D receptor polymorphisms in patients with cutaneous melanoma | Q35103696 | ||
| Calcium plus vitamin D supplementation and the risk of nonmelanoma and melanoma skin cancer: post hoc analyses of the women's health initiative randomized controlled trial | Q35170221 | ||
| Basal cell carcinomas: attack of the hedgehog | Q35687900 | ||
| Genetic architecture of mouse skin inflammation and tumour susceptibility | Q35702641 | ||
| Why the optimal requirement for Vitamin D3 is probably much higher than what is officially recommended for adults | Q35822347 | ||
| Evaluation of ergocalciferol or cholecalciferol dosing, 1,600 IU daily or 50,000 IU monthly in older adults | Q36158130 | ||
| Novel Hedgehog pathway targets against basal cell carcinoma | Q36727507 | ||
| An update on new and emerging options for the treatment of vitiligo | Q37121631 | ||
| Vitamin D receptor polymorphisms and the risk of cutaneous melanoma: a systematic review and meta-analysis | Q37279151 | ||
| New insights on therapy with vitamin D analogs targeting the intracellular pathways that control repigmentation in human vitiligo | Q37400818 | ||
| Serum 25-hydroxyvitamin D3 levels are associated with breslow thickness at presentation and survival from melanoma | Q37411677 | ||
| Vitamin D and melanoma | Q37413793 | ||
| Melanoma and vitamin D | Q37849442 | ||
| Vitamin D: can an upper limit be defined? | Q38758619 | ||
| Activation of vitamin D receptor (VDR)- and peroxisome proliferator-activated receptor (PPAR)-signaling pathways through 1,25(OH)(2)D(3) in melanoma cell lines and other skin-derived cell lines | Q39533263 | ||
| Antitumor effects of two less-calcemic vitamin D analogs (Paricalcitol and QW-1624F2-2) in squamous cell carcinoma cells | Q40181056 | ||
| In vitro comparison of the vitamin D endocrine system in 1,25(OH)2D3-responsive and -resistant melanoma cells | Q40195327 | ||
| Analysis of the vitamin D system in basal cell carcinomas (BCCs). | Q40518194 | ||
| Differential biological effects of 1,25-dihydroxyVitamin D3 on melanoma cell lines in vitro | Q40540470 | ||
| Differentiation of murine melanocyte precursors induced by 1,25-dihydroxyvitamin D3 is associated with the stimulation of endothelin B receptor expression | Q40704328 | ||
| Prediagnostic serum levels of 1,25-dihydroxyvitamin D and malignant melanoma | Q41081000 | ||
| Analysis of the vitamin D system in cutaneous malignancies. | Q42445625 | ||
| Regulation of Terminal Differentiation of Cultured Mouse Epidermal Cells by lα,25-Dihydroxyvitamin D3* | Q42449276 | ||
| Diet and risk of basal cell carcinoma of the skin in a prospective cohort of women | Q42452881 | ||
| Reduced serum 25-hydroxyvitamin D levels in stage IV melanoma patients | Q42458173 | ||
| The photoprotective effect of 1,25-dihydroxyvitamin D3 on ultraviolet light B-induced damage in keratinocyte and its mechanism of action | Q42461486 | ||
| Vitamin D and nonmelanoma skin cancer in a health maintenance organization cohort | Q42493066 | ||
| Human melanocytes as a target tissue for hormones: in vitro studies with 1 alpha-25, dihydroxyvitamin D3, alpha-melanocyte stimulating hormone, and beta-estradiol | Q42502557 | ||
| Expression profiling of vitamin D treated primary human keratinocytes | Q42597793 | ||
| Mice lacking 25OHD 1alpha-hydroxylase demonstrate decreased epidermal differentiation and barrier function | Q43906524 | ||
| 1,25-Dihydroxyvitamin D3 inhibits ultraviolet B-induced apoptosis, Jun kinase activation, and interleukin-6 production in primary human keratinocytes | Q44511478 | ||
| Antiapoptotic action of 1alpha,25-dihydroxyvitamin D3 in primary human melanocytes | Q44527461 | ||
| No evidence for amplification of 25-hydroxyvitamin D-1alpha-OHase (1alpha-OHase) or 1,25-dihydroxyvitamin D-24-OHase (24-OHase) genes in malignant melanoma (MM). | Q44958193 | ||
| Effectiveness of 1alpha-hydroxyvitamin D2 in inhibiting tumor growth in a murine transgenic pigmented ocular tumor model | Q45056963 | ||
| 1,25-Dihydroxyvitamin D3 and analogues protect primary human keratinocytes against UVB-induced DNA damage | Q45233914 | ||
| Polymorphisms of the VDR gene are associated with presence of solar keratoses on the skin | Q46468918 | ||
| Regulation of keratinocyte growth, differentiation, and vitamin D metabolism by analogs of 1,25-dihydroxyvitamin D. | Q46536788 | ||
| Antiproliferative effect of vitamin A and D analogues on adult human keratinocytes in vitro | Q46570303 | ||
| Skin cancer prevention: a possible role of 1,25dihydroxyvitamin D3 and its analogs | Q46614746 | ||
| Vitamin D receptor (VDR) ablation alters carcinogen-induced tumorigenesis in mammary gland, epidermis and lymphoid tissues | Q46660080 | ||
| Diet and risk of cutaneous malignant melanoma: a prospective study of 50,757 Norwegian men and women. | Q50952450 | ||
| Inhibition of tumor promotion in mouse skin by 1 alpha,25-dihydroxyvitamin D3. | Q53541686 | ||
| 1 alpha, 25-Dihydroxyvitamin D3 inhibits phorbol ester-dependent chemical carcinogenesis in mouse skin. | Q53557601 | ||
| Case-control study of melanoma and dietary vitamin D: implications for advocacy of sun protection and sunscreen use | Q68101387 | ||
| In vivo threshold for cutaneous synthesis of vitamin D3 | Q69354999 | ||
| Suppression of in vivo growth of human cancer solid tumor xenografts by 1,25-dihydroxyvitamin D3 | Q70156729 | ||
| Possible role of 1,25-dihydroxyvitamin D3-induced metallothionein in photoprotection against UVB injury in mouse skin and cultured rat keratinocytes | Q71145425 | ||
| Vitamin D receptor and growth inhibition by 1,25-dihydroxyvitamin D3 in human malignant melanoma cell lines | Q71435610 | ||
| 1,25-dihydroxyvitamin D3 receptors in human epithelial cancer cell lines | Q71858538 | ||
| 46 Determination of vitamin D and its metabolites in plasma | Q72847689 | ||
| 1,25-dihydroxyvitamin D3 and malignant melanoma: the presence of receptors and inhibition of cell growth in culture | Q72878839 | ||
| Efficacy and safety of vitamin D3 intake exceeding the lowest observed adverse effect level | Q73396246 | ||
| Conceptually new deltanoids (vitamin D analogs) inhibit multistage skin tumorigenesis | Q73939111 | ||
| Derivation of tolerable upper intake levels of nutrients | Q77292015 | ||
| 1,25-Dihydroxycholecalciferol (1,25-D3) inhibits the growth of squamous cell carcinoma and down-modulates p21(Waf1/Cip1) in vitro and in vivo | Q77861542 | ||
| 1alpha,25-dihydroxyvitamin D3 inhibits in vitro invasiveness through the extracellular matrix and in vivo pulmonary metastasis of B16 mouse melanoma | Q78171212 | ||
| Photoprotection by 1,25 dihydroxyvitamin D3 is associated with an increase in p53 and a decrease in nitric oxide products | Q79434792 | ||
| 1,25-Dihydroxyvitamin D and three low-calcemic analogs decrease UV-induced DNA damage via the rapid response pathway | Q80261517 | ||
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | vitamin D | Q175621 |
| carcinogenesis | Q1637543 | ||
| P304 | page(s) | 817.e1-11; quiz 827-8 | |
| P577 | publication date | 2012-11-01 | |
| P1433 | published in | Journal of the American Academy of Dermatology | Q15757046 |
| P1476 | title | Vitamin D in cutaneous carcinogenesis: part II. | |
| P478 | volume | 67 |
| Q41453247 | High prevalence of vitamin D deficiency in patients with xeroderma pigmetosum-A under strict sun protection. |
| Q26801494 | Immune Modulation by Vitamin D and Its Relevance to Food Allergy |
| Q26783118 | Melanoma risk perception and prevention behavior among African-Americans: the minority melanoma paradox |
| Q36059716 | Serum Vitamin D and Vitamin D Receptor Gene Polymorphism in Mycosis Fungoides Patients: A Case Control Study |
| Q36934873 | Serum level of vitamin D3 in cutaneous melanoma |
| Q55350966 | The Biological Activities of Vitamin D and Its Receptor in Relation to Calcium and Bone Homeostasis, Cancer, Immune and Cardiovascular Systems, Skin Biology, and Oral Health. |
| Q27004135 | The relevance of the vitamin D endocrine system (VDES) for tumorigenesis, prevention, and treatment of non-melanoma skin cancer (NMSC): Present concepts and future perspectives |
| Q34413846 | The role of vitamin D in reducing cancer risk and progression |
| Q26992094 | Tumor suppression in skin and other tissues via cross-talk between vitamin D- and p53-signaling |
| Q89087134 | Using a Mendelian randomization approach to explore a causal relationship between vitamin D and nonmelanoma skin cancer |
| Q89796086 | Vitamin D and other differentiation-promoting agents as neoadjuvants for photodynamic therapy of cancer |
| Q26773618 | Vitamin D and the skin: Focus on a complex relationship: A review |
| Q38412880 | Vitamin D in cancer chemoprevention |
| Q64326215 | Vitamin D levels in actinic keratosis: a preliminary study |
Search more.